{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transformed+Lymphoma&page=18", "query": { "condition": "Transformed Lymphoma", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 434, "total_pages": 44, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transformed+Lymphoma&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transformed+Lymphoma&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T06:00:14.884Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06863402", "title": "Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Richter Syndrome", "Diffuse Large B-Cell Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-11-15", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06863402" }, { "nct_id": "NCT00060021", "title": "Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "acupuncture therapy", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "pain therapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060021" }, { "nct_id": "NCT00005622", "title": "Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Multiple Myeloma and Malignant Plasma Cell Neoplasms", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "TBI", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "15 Years to 50 Years" }, "enrollment_count": 72, "start_date": "1996-05", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2012-10-25", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005622" }, { "nct_id": "NCT03534323", "title": "Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Richter Syndrome" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2018-07-12", "completion_date": "2026-07-01", "has_results": true, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 7, "location_summary": "Miami, Florida • Brewer, Maine • Boston, Massachusetts + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Brewer", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03534323" }, { "nct_id": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large B-cell Lymphoma", "DLBCL - Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "mosunetuzumab", "type": "DRUG" }, { "name": "glofitamab", "type": "DRUG" }, { "name": "obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2021-11-05", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 2, "location_summary": "Omaha, Nebraska • Philadelphia, Pennsylvania", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04889716" }, { "nct_id": "NCT05006716", "title": "A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Malignancy", "Marginal Zone Lymphoma", "Follicular Lymphoma", "Non-Hodgkin Lymphoma", "Waldenström Macroglobulinemia", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Mantle Cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Richter Transformation" ], "interventions": [ { "name": "Tacabrutideg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 689, "start_date": "2021-09-13", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05006716" }, { "nct_id": "NCT00952185", "title": "Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nonmalignant Neoplasm", "Viral Infection" ], "interventions": [ { "name": "cytology specimen collection procedure", "type": "OTHER" }, { "name": "fluorescent antibody technique", "type": "OTHER" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2008-11", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00952185" }, { "nct_id": "NCT00098826", "title": "SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Undifferentiated Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Acute Promyelocytic Leukemia (M3)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Blastic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "ispinesib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-11", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098826" }, { "nct_id": "NCT00006040", "title": "Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "etoposide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "yttrium Y 90 monoclonal antibody M195", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-04", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006040" }, { "nct_id": "NCT02392039", "title": "Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Loratadine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "OTHER", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-12-14", "completion_date": "2018-04-04", "has_results": false, "last_update_posted_date": "2019-04-23", "last_synced_at": "2026-10-24T06:00:14.884Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392039" } ] }